The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Science, Nankai University, Tianjin 300071, China.
Biomaterials. 2012 Jan;33(3):762-70. doi: 10.1016/j.biomaterials.2011.10.037. Epub 2011 Nov 4.
One of the major challenges of tissue-engineered small-diameter blood vessels is restenosis caused by thrombopoiesis. The goal of this study was to develop a 3D gradient heparinized nanofibrous scaffold, aiding endothelial cells lined on the lumen of blood vessel to prevent thrombosis. The vertical graded chitosan/poly ɛ-caprolactone (CS/PCL) nanofibrous vessel scaffolds were fabricated with chitosan and PCL by sequential quantity grading co-electrospinning. To mimic the natural blood vessel microenvironment, we used heparinization and immobilization of vascular endothelial growth factor (VEGF) in the gradient CS/PCL. The quantity of heparinized chitosan nanofibers increased gradually from the tunica adventitia to the lumen surfaces in the gradient CS/PCL wall of tissue engineered vessel. More heparin reacted to chitosan nanofiber in gradient CS/PCL than in uniform CS/PCL nanofibrous scaffolds. Antithrombogenic properties of the scaffolds were enhanced by the heparinization of these scaffolds, as shown by activated partial thromboplastin time and platelet adhesion assay. Compared to the uniform CS/PCL scaffold, the release of VEGF from the gradient CS/PCL was more stable and sustained, and the burst release of VEGF was reduced approximately 42.5% within the initial 12 h. The adhesion and proliferation of human umbilical vein endothelial cells (HUVEC) were enhanced on the gradient CS/PCL scaffold. Furthermore, HUVEC grew and formed an entire monolayer on the top side of the gradient CS/PCL scaffold. Therefore, use of vertical gradient heparinized CS/PCL nanofibrous scaffolds could provide an approach to create small-diameter blood vessel grafts with innate properties of mammalian vessels of anticoagulation and rapid induction of re-endothelialization.
组织工程小直径血管面临的主要挑战之一是由血栓形成引起的再狭窄。本研究的目的是开发一种 3D 梯度肝素化纳米纤维支架,以帮助内皮细胞排列在血管管腔的内壁上,从而防止血栓形成。通过顺序数量分级共静电纺丝制备垂直分级壳聚糖/聚己内酯(CS/PCL)纳米纤维血管支架,壳聚糖和 PCL 采用壳聚糖和 PCL。为了模拟天然血管微环境,我们在梯度 CS/PCL 中使用肝素化和血管内皮生长因子(VEGF)固定化。梯度 CS/PCL 壁组织工程血管中,肝素化壳聚糖纳米纤维的数量从外膜逐渐增加到内腔表面。与均匀的 CS/PCL 纳米纤维支架相比,梯度 CS/PCL 中的肝素化壳聚糖纳米纤维反应更多。这些支架的肝素化增强了支架的抗血栓形成特性,如激活部分凝血活酶时间和血小板黏附试验所示。与均匀的 CS/PCL 支架相比,VEGF 从梯度 CS/PCL 的释放更加稳定和持续,并且 VEGF 的爆发释放在最初 12 小时内减少了约 42.5%。人脐静脉内皮细胞(HUVEC)在梯度 CS/PCL 支架上的黏附和增殖得到增强。此外,HUVEC 在梯度 CS/PCL 支架的顶部生长并形成完整的单层。因此,使用垂直梯度肝素化 CS/PCL 纳米纤维支架可以提供一种方法来创建具有天然抗凝和快速诱导再内皮化特性的小直径血管移植物。